NDA 205223 · Alembic Therap
Nuvessa
Metronidazole · Vaginal · Nitroimidazole Antimicrobial
Last checked: Nov 19, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Mar 24, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
728
132 Phase 3, 52 recruiting
FAERS reports
48,241
42,012 serious, 5,419 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2023.
NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in females 12 years of age and older. ( 1 )
Mechanism: Metronidazole is an antimicrobial drug [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 3, 2018 Supplement 2 · Efficacy · priority review LabelLetter
- Mar 24, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewPediatric Medical Review
1 products under this application
- NUVESSA · METRONIDAZOLE 1.3% · GEL, VAGINAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.
- Helicobacter Eradication Aspirin TrialPivotal-lookingCompleted
University of NottinghamAcademic, hospital or other
NCT01506986 · 30,024 participants · Start Mar 2012 · Primary completion Oct 31, 2017
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg · For: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Durham, United Kingdom · 6 sites in all
- The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive TractPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04189744 · 5,436 participants · Start Dec 15, 2019 · Primary completion Oct 21, 2022
Drug: IPTp-sulphadoxine-pyrimethamine plus metronidazole; IPTp-dihydroartemisinin-piperaquine plus metronidazole and 1 more · For: Pregnancy Malaria; Bacterial Vaginoses; Trichomonas Vaginitis
Sites: Nchelenge, Zambia
- Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General PopulationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT02112214 · 5,224 participants (planned) · Start Jun 2014 · Primary completion Dec 2029
Drug: 10-day bismuth-based quadruple therapy · For: Gastric Cancer; Helicobacter Pylori Infection
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 11 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV TransmissionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00021671 · 3,720 participants
Drug: Erythromycin; Nevirapine and 2 more · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- Antibiotic Prophylaxis in Metabolic Bariatric SurgeryPivotal-lookingStatus unknown
General Committee of Teaching Hospitals and Institutes, EgyptGovernment (non-federal)
NCT06510452 · 3,352 participants (planned) · Start Oct 1, 2024 · Primary completion Dec 1, 2025
Drug: 2000 mg of Cefazolin; 500 mg of Metronidazole IV and 1 more · For: Antibiotic Reaction; Wound Infection Superficial; Wound Infection Deep and 2 more
Sites: Alexandria, Egypt; Amersfoort, Netherlands
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.Pivotal-lookingCompleted
Zealand University HospitalAcademic, hospital or other
NCT04803422 · 3,193 participants · Start Apr 1, 2021 · Primary completion May 31, 2024
Drug: Antibiotic · For: Complicated Appendicitis
Sites: Slagelse, Denmark · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,672
- nausea3,469
- off label use3,384
- diarrhoea2,721
- vomiting2,342
- pyrexia2,301
- headache2,261
- abdominal pain2,126
- pain2,121
- fatigue1,960
- dizziness1,689
- condition aggravated1,638
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 459 |
| 2005 | 480 |
| 2006 | 482 |
| 2007 | 511 |
| 2008 | 320 |
| 2009 | 676 |
| 2010 | 858 |
| 2011 | 1,164 |
| 2012 | 1,431 |
| 2013 | 1,112 |
| 2014 | 1,451 |
| 2015 | 2,167 |
| 2016 | 2,469 |
| 2017 | 2,511 |
| 2018 | 4,196 |
| 2019 | 4,496 |
| 2020 | 3,830 |
| 2021 | 3,904 |
| 2022 | 3,418 |
| 2023 | 3,478 |
| 2024 | 3,179 |
| 2025 | 3,456 |
| 2026 | 2,190 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuvessa (Metronidazole)
2024 spending
$130K
Beneficiaries
439
534 claims
Per beneficiary
$295
$40.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $58,173 |
| 2021 | $62,698 |
| 2022 | $73,522 |
| 2023 | $109,954 |
| 2024 | $129,630 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical pharmacokinetics of metronidazole: a systematic review and meta-analysis.
Shahzad I, Alasmari MS, Zamir A, et al. · Antimicrob Agents Chemother 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease.
Wiesenfeld HC, Meyn LA, Darville T, et al. · Clin Infect Dis 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Alembic Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.